Following are extracts from the CEO Annual Report:?the past 12...

Following are extracts from the CEO Annual Report:
?the past 12 months we have continued to develop our neuroprotectant compound EBC-159 which is a potential treatment for Alzheimers and canine cognitive decline. Initial animal trials for this drug are currently under development. In addition, we are developing two veterinary nutraceutical products to treat cognitive decline and obesity in dogs. Plans are to initially market these products in the USA where there is a strong demand and regulatory requirements are less stringent than here in Australia.
Our collaboration with the German fragrance and flavour company Symrise continues to be very positive. Earlier this year we entered into an antifungal R&D collaboration with Symrise and they are currently screening a range of our extracts.
In the coming year we plan to further assess our anticancer lead compound EBC-23, which has shown activity against prostrate and breast cancers and to reinitiate our antibiotic discovery program.
We are also well advanced in negotiations with a major international cosmetic company to license one of our patents for a specific rainforest plant extract.?
So apart from EBC-46 and Qbiotics they have 4 main other things on the go:
1. EBC-159 Alzheimers
2. Symrise extract screening
3. EBC-23 prostrate and breast cancer
4. Rainforest plant extract to do with something cosmetic?
What I like the sound of is the veterinary neutricutical products. The what seems to be easily entered USA market could well be a goldmine. Does anyone know what hoops they would have to jump through for this?